Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection; (NOTE: a designation of type I or type II should be made by the local pathologist if possible); mixed histologies containing type I or type II will be allowed provided that they contain >= % of the papillary component Patients must have tissue available and be willing to submit for independent pathologic review in order to classify type I versus type II papillary disease Type or diabetes requiring anti-hyperglycemic medication (e.g. metformin, glipizide, insulin) Patients with Diabetes Type I or uncontrolled Type II as judged by the Investigator Wild-type TP status Prior history of anaphylaxis with this product type Type I or type II diabetes, or Hgb Ac > .% EXCLUSION - INFUSION: Uncontrolled autoimmune disease needing systemic steroids or steroid sparing agents except for hypothyroidism or type I diabetes Participant has a concurrent diagnosis of type I or type II diabetes that is being treated with insulin or an oral antidiabetic agent; (participants whose type II diabetes is controlled with diet and/or exercise alone are eligible provided they meet all other eligibility criteria) Part B: Must have a type of malignancy that is being studied. Patients may have neurofibromatosis type or Subjects with neurofibromatosis type (NF) are also eligible There is no limitation of amount or the type of prior therapy or drugs Has a confirmed diagnosis of type diabetes or type diabetes that has been diagnosed by an HbAc ? ., or is on any hypoglycemic medications (insulin, metformin, etc) FOR ALL PHASES (Ib AND II): Type I diabetes or patients on insulin therapy are not allowed; uncontrolled type II diabetes not allowed (glycosylated hemoglobin [HbAc] > .) History of autoimmune disease except for controlled, treated thyroidism or Type diabetes Tumor type: Pathologically confirmed MPNST, with or without underlying diagnosis of neurofibromatosis type (diagnostic criteria for neurofibromatosis type ) Pedunculated polyps (as defined by Paris Classification type Ip or Isp) Patients with gliomatosis cerebri type or Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible Patients with uncontrolled type or type diabetes; patients with an elevated risk of hyperglycemia should be excluded from study Patients must not have type I or II diabetes that requires anti-hyperglycemic medication Special cases of high-risk lymphoma, including but not limited to: plasma dendritic cell type, hepato-splenic T cell type, gamma delta panniculitic T cell type, muco-cutaneous natural killer (NK) cell type, and stage III-IV nasal NK cell type\r\n* Primary treatment failure\r\n* Relapse after autologous SCT\r\n* Non-CR after salvage regimen\r\n*In first CR or any later CR Type diabetes or uncontrolled Type diabetes Patients with uncontrolled Diabetes Type I or Type II Histologically or cytologically confirmed recurrent or metastatic SCCHN\r\n* All primary sites are eligible excluding World Health Organization (WHO) type III or EpsteinBarr virus (EBV) nasopharyngeal (WHO type I and WHO type II allowed as long as they are EBV negative) Epithelial type Patients with type II diabetes currently already on metformin Patients with diabetes type I or uncontrolled type II (HbAc > % assessed locally) as judged by the investigator Participants with fasting blood glucose values that are > institutional ULN; in addition, patients with type diabetes will also be excluded; however, patients with type diabetes will be allowed if diagnosed >= months prior to enrollment, and if presenting with regular hemoglobin AC (HbAC) =< % at screening Subjects with Type II diabetes are only allowed if their HbAC is less than percent at study entry. History of Type or Type diabetes requiring regular medication Patients who have had prior therapy with chemokine receptor type (CXCR) inhibitors Patients must not have active or history of clinically significant autoimmune disorders/conditions including type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria Patients must not have active or history of clinically significant autoimmune disease, defined as requiring systemic therapy, such as type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria Patients undergoing either a Type II or III radical hysterectomy (Piver Classification) Second degree AV block Type (Mobitz Type / Wenckebach type) Patients with abnormal fasting glucose values (> mg/dl) at screening will be excluded; in addition, patients with type diabetes will also be excluded; however, patients with type diabetes will be allowed if diagnosed >= months prior to enrollment, and if presenting with regular hemoglobin AC (HbAC) =< % at screening Type diabetes or uncontrolled Type diabetes Part A: Any type of solid tumor (\all comer\) History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes Type or diabetes requiring antihyperglycemic medication Confirmed diagnosis of refractory celiac disease Type (RCD-II) Patients with Diabetes Type I or uncontrolled Type II (HbAc > mmol/mol assessed locally) as judged by the Investigator Fracture is closed, Gustilo Type I or II. Type or Type diabetes Type I Diabetes Patients with any type of brain tumor will be eligible for participation Type I diabetes Type II diabetes requiring chronic therapy with insulin Type or diabetes requiring anti-hyperglycemic medication Type I diabetes or uncontrolled type II diabetes Type or type diabetes Type diabetes Use of type III antiarrhythmics (e.g. amiodarone) Group : Patients known to be KIT wild type. No limitations exist for type or amount of prior therapy type diabetes Fitzpatrick skin type I-VI Reported current diagnosis or history of type I diabetes or type diabetes. Individuals with Fitzpatrick skin type I are ineligible Individuals with Fitzpatrick skin type V or VI are ineligible Patients with Fitzpatricks scale skin type IV-VI Any type of ostomy Any disease type Group III: Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled type II diabetes (glucose levels < ) may be included Have a diagnosis of any type of NHL and =< years from the last treatment Patients with diabetes type or uncontrolled type II (HbAc > % assessed locally)